PRLD Prelude Therapeutics, Incorporated
Price Chart
Executive Summary
Prelude Therapeutics reported its full-year 2025 financial results, showing improved losses and reduced expenses, while providing key R&D updates including FDA clearance of the IND for its JAK2V617F inhibitor PRT12396 and progress on its KAT6A degrader program. The company maintains a cash runway into Q2 2027 with $106.4 million in liquidity.
Key Financial Metrics
Actionable Insight
Traders should monitor upcoming IND filings and Phase 1 initiations for PRT12396 and PRT13722 as near-term catalysts. The improved cash runway reduces near-term dilution risk, but the company remains pre-revenue with no product sales, so future value hinges on clinical execution.
Key Facts
- FDA cleared the IND for PRT12396 (JAK2V617F inhibitor), with Phase 1 initiation expected in Q2 2026 in patients with polycythemia vera and myelofibrosis.
- IND filing for PRT13722 (KAT6A degrader) expected mid-2026, with Phase 1 initiation in second half of 2026.
- Cash, cash equivalents, and marketable securities totaled $106.4 million as of December 31, 2025, funding operations into Q2 2027.
- 2025 net loss was $99.5 million ($1.29/share), improved from $127.2 million ($1.68/share) in 2024.
- Revenue increased to $12.14 million in 2025 from $7.0 million in 2024, primarily from collaboration and license agreements.
Financial Impact
Revenue increased 73% YoY to $12.14M; net loss narrowed by $27.7M. R&D and G&A expenses declined significantly due to reduced stock-based compensation and discontinued trials.
Risk Factors
- High dependence on clinical development success of early-stage assets with no guaranteed outcomes.
- Potential for future dilution if additional capital is needed beyond 2027.
- Forward-looking statements are subject to significant risks, including regulatory delays, trial enrollment issues, and manufacturing challenges.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252633 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 12, 2026
28d ago
|
8-K
| $4.64 $4.34 | ▼ −6.47% | ▼ −6.54% | $3.84 (−17.24%) |
|
May 12, 2026
28d ago
|
Press Release
| $4.64 $4.34 | ▼ −6.47% | ▼ −6.54% | $3.84 (−17.24%) |
|
Apr 28, 2026
6w ago
|
3
| $4.27 $4.67 | ▲ +9.37% | ▲ +6.26% | $3.84 (−10.07%) |
|
Apr 21, 2026
7w ago
|
Insider Cluster
| $4.27 $4.84 | ▲ +13.35% | ▲ +10.24% | $3.84 (−10.07%) |
|
Apr 20, 2026
7w ago
|
8-K
| $4.51 $4.52 | ▲ +0.22% | ▼ −0.69% | $3.84 (−14.86%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $4.51 $4.52 | ▲ +0.22% | ▼ −0.69% | $3.84 (−14.86%) |
|
Apr 15, 2026
7w ago
|
8-K
| $5.52 $4.31 | ▼ −21.92% | ▼ −23.56% | $3.84 (−30.43%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $3.60 $3.43 | ▼ −4.72% | ▼ −3.82% | $3.84 (+6.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access